Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Biogen takes territorial rights to Stoke’s Dravet program: Deals Report

Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more

February 19, 2025 2:01 AM UTC

More than two years into the tenure of CEO Christopher Viehbacher, Biogen is continuing to reshape itself via dealmaking. In its latest move, the big biotech has obtained rights outside of North America to an antisense therapy for Dravet syndrome, a rare seizure disorder, from Stoke.

Biogen Inc. (NASDAQ:BIIB) said Tuesday that it is paying Stoke Therapeutics Inc. (NASDAQ:STOK) $165 million up front for rights to zorevunersen, an antisense oligonucleotide targeting SCN1A. The deal, which excludes rights in the U.S., Canada and Mexico, includes another $385 million in milestones, plus royalties; the parties have agreed to split development costs 70/30, with Stoke shouldering the larger load...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article